Obesity hypoventilation syndrome is defined as alveolar hypoventilation while awake in an obese individual where there is no other cause of the hypoventilation (such as a sedating drug). Ninety percent of people with obesity hypoventilation syndrome (OHS) also have an associated obstructive sleep apnea.The mainstay of treatment in OHS is to provide breathing support, often through the use of continuous positive airway pressure (CPAP) or bilevel.
The global market for Obesity Hypoventilation Syndrome Treatment is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Obesity Hypoventilation Syndrome Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Obesity Hypoventilation Syndrome Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Obesity Hypoventilation Syndrome Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Obesity Hypoventilation Syndrome Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Obesity Hypoventilation Syndrome Treatment players cover Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc and Strides Pharma Science Limited, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Obesity Hypoventilation Syndrome Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Obesity Hypoventilation Syndrome Treatment market, with both quantitative and qualitative data, to help readers understand how the Obesity Hypoventilation Syndrome Treatment market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Obesity Hypoventilation Syndrome Treatment market and forecasts the market size by Type (Oxygen Therapy, Non-invasive Mechanical Ventilation and Drug Therapy), by Application (Hospital, Clinics and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Oxygen Therapy
Non-invasive Mechanical Ventilation
Drug Therapy
Other
Segmentation by application
Hospital
Clinics
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Accord Healthcare Limited
Avet Pharmaceuticals Inc
Nostrum Laboratories Inc
Lannett Co Inc
Strides Pharma Science Limited
X Gen Pharmaceuticals Inc
ResMed
Koninklijke Philips NV
Hikma Pharmaceuticals
Lincare Holdings
Chapter Introduction
Chapter 1: Scope of Obesity Hypoventilation Syndrome Treatment, Research Methodology, etc.
Chapter 2: Executive Summary, global Obesity Hypoventilation Syndrome Treatment market size and CAGR, Obesity Hypoventilation Syndrome Treatment market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Obesity Hypoventilation Syndrome Treatment revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Obesity Hypoventilation Syndrome Treatment revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Obesity Hypoventilation Syndrome Treatment market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV and Hikma Pharmaceuticals, etc.
Chapter 14: Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Obesity Hypoventilation Syndrome Treatment. Industry analysis & Market Report on Obesity Hypoventilation Syndrome Treatment is a syndicated market report, published as Global Obesity Hypoventilation Syndrome Treatment Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Obesity Hypoventilation Syndrome Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.